Business Wire

ADVA unveils commercially ready disaggregated cell site gateway solution at TIP ’19

13.11.2019 15:15:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced the commercial readiness of its disaggregated cell site gateway (DCSG) solution at the Telecom Infra Project (TIP) Summit. Powered by ADVA’s Ensemble Activator network operating system (NOS), the integrated white box solution comes with a comprehensive bundle of installation, commissioning and monitoring services for rapid network deployment. The technology is currently on display in a 5G demo at the TIP Summit with ADVA’s software running on Edgecore’s new family of DCSG devices. The showcase highlights how mobile network operators (MNOs) now have an easy and cost-effective route to mass small cell deployment for 5G services. Already successful in a series of trials in global MNO networks, Ensemble Activator is the industry’s only true carrier-grade NOS for bare-metal switches.

“This is a landmark moment for mobile networks. Now that MNOs can leverage our DCSG solution as a simple and complete answer for evolving their infrastructure to 5G, the shackles are off. We’re empowering them to roll out widespread small cell networks in a way that’s simple, affordable and future-proof. Our technology and complete service bundle make the transition easy so that MNOs are free to focus instead on the business opportunities that 5G offers,” said Eli Angel, VP, product line management, Ethernet access, ADVA. “This TIP demo also highlights the value of openness and disaggregation in mobile networks. By enabling software to be separated from hardware, we’re giving operators the freedom to select the ideal technology combination for their needs and harness the latest and greatest innovation.”

The new DCSG solution has been engineered to TIP’s white box gateway specifications. By giving MNOs the power to move away from a closed proprietary system to an open, disaggregated and vendor-neutral infrastructure, it provides the opportunity to massively increase network efficiencies. What’s more, the new DCSG technology enables an open approach, accelerating innovation cycles and reducing CAPEX. As well as providing a NOS, protocol support, dynamic configurability, and manageability, the DCSG solution also delivers IEEE 1588 timing with optional SFP-based GNSS backup. Powered by Ensemble Activator, the DCSG technology is the second commercial offering ADVA has developed for TIP, following its successful rollout of a packet optical solution built around the Voyager optical white box.

“It’s great to see how rapidly this community has produced results. After only 12 months, our initiative has pushed DCSG technology from concept to reality and created a solution ready for deployment in live networks. With ADVA’s Ensemble Activator becoming generally available, operators have a clear roadmap to the next generation of mobile networks,” commented Luis MartinGarcia, co-lead, DCSG project group, TIP. “MNOs can now harness a complete and fully tested DCSG solution that enables them to address today’s key challenges. It opens the door to the deployment of the hundreds of thousands of cell site gateways needed to address the mobile backhaul demands of 5G.”

“What we’re presenting to the industry here at TIP ’19 is a new and innovative method of building and deploying telecom networks. We’re showcasing a way to tackle the most pressing challenges of 4G and emerging 5G mobile networks by enabling open technology choices and delivering the cost-efficiency of disaggregation. ADVA’s Ensemble Activator running on our cell site gateway family of products offers the ultimate route to lower costs and increased service flexibility,” said Matt Roman, VP, marketing and product management, Edgecore. ”The rapid success of this project is due to the close collaboration of our teams. Working together with ADVA, we’ve built an integrated technology which, when coupled with a rich set of supporting services, enables MNOs to utilize a truly cohesive open cell site solution.”

ADVA’s new DCSG solution will be on display at the TIP Summit’s LiveLab from November 13 to 14.

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release

Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release

As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye